S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines

Trial Profile

S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab; Capecitabine
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms SALTO
  • Most Recent Events

    • 15 Aug 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
    • 15 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 27 Jan 2014 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top